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Vulval intraepithelial neoplasia (VIN) is thought to be the
premalignant phase of human papillomavirus (HPV)-associ-
ated vulval squamous cell carcinoma (VSCC). Various mo-
lecular events have been suggested as markers for progres-
sion from VIN to VSCC, but loss of heterozygosity (LOH) in
vulval neoplasia has rarely been studied in this context. We
performed LOH analysis by polymerase chain reaction (PCR)
amplification of polymorphic microsatellite markers at 6
chromosomal loci (17p13-p53, 9p21-p16, 3p25, 4q21, 5p14
and 11p15). The presence of HPV was assessed using consen-
sus PCR primers and DNA sequencing. To examine any
association between LOH and the presence of invasive dis-
ease, we analyzed 43 cases of lone VIN III, 42 cases of lone
VSCC and 21 cases of VIN with concurrent VSCC. HPV DNA
was detected in 95% of lone VIN III samples and 71% of lone
VSCC samples. Fractional regional allelic loss (FRL) in VIN
associated with VSCC was higher than in lone VIN (mean
FRL 0.43 vs. 0.21, p < 0.005). LOH at 3p25 occurred signifi-
cantly more frequently in HPV-negative VSCC than in HPV-
positive VSCC (58% vs. 22%, p < 0.04). These data suggest
that genetic instability in VIN, reflected by LOH, may in-
crease the risk of invasion. In addition, molecular events
differ in HPV-positive and -negative VSCC and 3p25 may be
the site of a tumor suppressor gene involved in HPV-inde-
pendent vulval carcinogenesis.
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Vulval intraepithelial neoplasia (VIN) is thought to be the
premalignant phase of invasive vulval squamous cell carcinoma
(VSCC). This hypothesis is based on the observation that VIN
frequently occurs adjacent to VSCC,1 that VIN and a subgroup of
VSCC are associated with similar risk factors [smoking,2 immu-
nosuppression3 and human papillomavirus (HPV) infection2,4] and
that VIN is a monoclonal neoplastic condition.5 The risk of pro-
gression of VIN to VSCC is unclear.6,7
Limited evidence is available about molecular events in vulval
carcinogenesis. Loss of heterozygosity (LOH) is a common mo-
lecular event in malignancy, but has been studied only in relatively
small numbers of VIN and VSCC.8–11 We set out to document the
LOH rates in VIN and VSCC in a larger series, to examine the
relationship between the 2 conditions. Events common to both
conditions could be early events in vulval carcinogenesis. Events
occurring in VIN associated with VSCC but not in lone VIN could
be markers for risk of progression to VSCC.
Because human papillomavirus (HPV) is thought to be involved
in the development of VIN-associated VSCC, but is not found so
often in VSCC occurring in the absence of VIN,2 we also per-




Patients with VIN and VSCC diagnosed between 1989 and 1997
were identified using the computerized database of the pathology
departments of St. Bartholomew’s and the Royal London Hospi-
tals. Samples containing both normal and neoplastic tissue were as
follows: 43 cases of VIN III alone, 42 cases of VSCC alone and 21
cases of VIN associated with concurrent VSCC (18 of which had
the concurrent VSCC still remaining on the specimen blocks after
serial sectioning). Of the 60 VSCC cases, 24 were stage I, 11 were
stage II, 9 were stage III, 3 were stage IV and in 13 information for
accurate staging was not available. Of the 21 cases of VIN asso-
ciated with VSCC, 18 were VIN III, 2 were VIN II and 1 was VIN
I. The following other epithelial abnormalities were observed:
squamous cell hyperplasia (9 cases), lichen sclerosus (7 cases),
lichen planus (1 case) and Paget’s disease (1 case). The relevant
paraffin-embedded tissue samples underwent serial sectioning as
follows: one 4-mm section was mounted, stained with hematoxylin
and eosin (H&E), covered and used as a reference slide. One
10-mm section was also stained with H&E, but left uncovered for
microdissection. For clarity, the VIN and VSCC samples from the
21 patients with a concurrent diagnosis of both conditions will
henceforth be termed “VIN(1)” and “VSCC(1),” respectively.
VIN samples from patients without associated VSCC will there-
fore be termed “VIN(2)” and VSCC samples from patients with-
out associated VIN will be termed “VSCC(2)”.
Microdissection of tissue samples and extraction of DNA
The uncovered H&E-stained 10-mm section was mounted on a
dissecting microscope and compared with the reference slide.
Areas of tissue containing .70% VSCC, .70% VIN or 100%
normal cells were identified and microdissected. The tissue was
placed in 100 ml of 10% Chelex chelating resin (Sigma, St. Louis,
MO) in distilled water; then 1 ml of 20 mg/ml proteinase K was
added to the tube, which was vortexed, placed in a shaking water
bath at 56°C for 30 min and boiled for 8 min. The sample was
Grant sponsor: Gynaecology Cancer Research Fund; Grant sponsor:
Stroyberg Vagn Jensen Foundation.
*Correspondence to: The Gynaecological Oncology Unit, St. Bar-
tholomew’s and the Royal London Hospitals Medical College, Queen
Mary and Westfield College, West Smithfield, London EC1A 7BE, UK.
Fax: 144-20-7601-7652. E-mail: i.j.jacobs@mds.qmw.ac.uk
Received 10 January 2001; Revised 11 May 2001; Accepted 25 May
2001
Int. J. Cancer: 94, 896–900 (2001)
© 2001 Wiley-Liss, Inc.
Publication of the International Union Against Cancer
centrifuged at 10,000g for 10 min to pellet any remaining debris,
then 1–5 ml of the supernatant was used directly in the polymerase
chain reaction (PCR).
Amplification of polymorphic microsatellite markers
PCR was performed in a volume of 20 ml, containing approx-
imately 20–100 ng DNA, 0.2 mM deoxyribonucleotide triphos-
phates, 0.25 U of Taq supreme DNA polymerase (Hellena Bio-
sciences, Sunderland, UK), 13 buffer (supplied with enzyme), 1.5
pmol of forward primer, 2 pmol of reverse primer and 0.5 pmol of
32P-labeled forward primer. PCR was performed in a Touchdown
Thermal Cycler (Hybaid, Ashford, UK). Table I shows the chro-
mosomal loci, primer pairs used to study amplify polymorphic
repeats, magnesium concentrations and annealing temperatures.
All PCR reactions were prepared according to the following pro-
tocol: DNA denaturation for 5 min at 95°C, hot start at 85°C, 35
cycles of denaturation at 95°C for 40 sec (ramped at 1°C/sec,
obviating the requirement for a separate extension step) and 30 sec
at the annealing temperature. This procedure was followed by a
final extension step at 72°C for 5 min.
Separation, visualization and interpretation of LOH analysis
PCR products
The PCR products were electrophoresed on a 5% denaturing
polyacrylamide gel. Autoradiography was performed. LOH was
scored as complete loss of 1 allele or .50% reduction in intensity
of 1 of the alleles from the neoplastic tissue relative to the normal
tissue of the same patient.9 All autoradiographs were read by 2
individuals (A.N.R., A.R.) who were blinded as to the histologic
type of the samples. Examples are shown in Figure 1.
Detection and sequencing of HPV DNA
PCR volume and concentrations were as above, but we used 20
pmol each of consensus genital type HPV L1 gene primers GP51
and GP61 (according to Kohlberger et al.4) and 3.5 mM Mg21.
PCR was performed using a 3-min denaturation step at 94°C
followed by 40 cycles of denaturation at 94°C for 1 min, annealing
at 48°C for 2 min and extension at 72°C for 1.5 min. A final
extension step at 72°C for 7 min was performed. HeLa cell DNA
was used as the positive control and cross-contamination was
checked for using water controls. PCR products were electropho-
resed on a 2% agarose gel and visualized using ethidium bromide
staining and ultraviolet illumination. The amplification product
from the above reaction was cut out of the agarose gel using a
sterile scalpel blade. DNA was extracted from the gel using a
commercial kit (QIAquick Gel Extraction Kit, Qiagen, Crawley,
UK), following manufacturer’s instructions. DNA sequencing was
performed using a commercial kit (ABI Prism dRhodamine Ter-
minator Cycle Sequencing Ready Reaction Kit, PE Biosystems,
Warrington, UK), following manufacturer’s instructions. Samples
were analyzed on an ABI Prism 377 automatic sequencer (PE
Biosystems). Data was analyzed using the manufacturer’s software
and the output was entered onto the National Center for Biotech-
nology Information BLAST search facility (http://www.ncbi.nlm.
nih.gov/BLAST/) for sequence comparison with known HPV
types. Sequences with a greater than 90% match to a known type
were classified as that type. Sequences with less than 90% match
were classified as unknown type.
Age-matching of comparison groups
Where appropriate, samples from one group were matched with
samples from a comparison group, such that the patients’ ages fell
within 63 years of the age of the sample with which it was being
compared. Unmatched samples were excluded from the analysis.
Statistical analysis
Proportions of informative samples showing LOH at individual
loci were compared using Fisher’s exact test or x2 test, where
appropriate. To take into account the differing proportions of
noninformative cases in the different sample groups, we calculated
the fractional regional allelic loss (FRL) for each sample.12 FRL
for each sample was the total number of loci undergoing LOH/total
number of informative loci. FRL scores for sample groups were
compared using the nonparametric Wilcoxon test. Ages of differ-
ent sample groups were compared overall using 1-way analysis of
variance and the Bonferroni post hoc test for comparisons between
individual groups. Stage distribution between groups was com-
pared using the Kolmogorov-Smirnov test. Significance was taken
at the 5% level.
RESULTS
DNA was successfully extracted and amplified with all primers
from all samples. Proportions of informative samples showing
LOH at individual loci, according to sample group, are shown in
TABLE I – LOCI STUDIED, PRIMER PAIRS, ANNEALING TEMPERATURES AND MAGNESIUM CONCENTRATIONS
Chromosomal




17p13.1 (p53) TP53 AGGGATACTATTCAGCCCCGAGGTG 58 3.5
ACTGCCACTCCTTGCCCCATTC
9p21 (p16) D9S171 AGCTAAGTGAACCTCATCTCTGTC 55 5.0
ACCCTAGCACTGATGGTATAGTCT
3p25 D3S1360 GACCCCGGGCTCCACAGCAAA 60 3.5
CCTGGCCTCTTCGGGGTGAC
4q21-23 D4S2458 GGCACATGAAAATGGCGAATG 55 3.5
TTCCTTCCCCTGTAGCTGCCC
5p14-13 D5S661 AGAATGTTTCCTGTGTATGTGC 55 5.0
CAAAATCCCAATGTCTCTGC
11p15.5 D11S922 GGGGCATCTTTGGCTA 55 4.5
TCCGGTTTGGTTCAGG
FIGURE 1 – Autoradiographs showing examples of loss of heterozy-
gosity in vulval intraepithelial neoplasia (VIN) and/or concurrent
vulval squamous cell carcinoma (VSCC). N, normal tissue; V, VIN; T,
VSCC. (a) Loss of upper allele at p53 locus in VIN and VSCC from
same patient. (b) Loss of lower allele at p16 locus in VIN, but retention
of lower allele in VSCC from same patient.
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Figure 2. The number of samples in each group, median age and
age ranges are shown in Table II. FRL in VIN(1) was significantly
greater than in VIN(2) (mean FRL 0.43 vs. 0.21, p , 0.005).
Seventeen of 21 VIN(1) samples were successfully age-matched
with a VIN(2) sample. FRL in age-matched VIN(1) was signif-
icantly greater than in age-matched VIN(2) (mean 0.35 vs. 0.16,
p , 0.03). FRL in VIN(1) was significantly greater than in
VSCC(1) (mean FRL 0.43 vs. 0.21, p , 0.02). This finding was
surprising as VSCC(1) would be expected to have arisen from
adjacent VIN(1) and therefore losses occurring in the VIN should
also occur in the VSCC. A possible explanation for this discrep-
ancy was contamination of VSCC(1) samples by nonneoplastic
stromal cells or infiltrating lymphocytes.
We scored the samples for lymphocytic infiltration and the
presence of stromal cells within VSCC(1) using a 6-point scale:
up to 3 points for lymphocytic infiltration and up to 3 points for
stromal contamination (data not shown). Scoring was performed
by 1 individual (D.H.) who was blinded as to whether samples
were VSCC(1) or VSCC(2). The maximum contamination ex-
hibited by any sample was 4 out of a possible 6. Five of 9
VSCC(1) samples showing LOH at 1 or more locus scored 4 on
this scale.
The p16 locus was lost significantly more in VIN(1) than in
VIN(2) (p , 0.05). The frequency of LOH at the p53 locus was
higher in VSCC(1) (33%) than in VIN(1) (23%) and VIN(2)
(17%), but these differences were not statistically significant.
Overall, there were significant differences between the ages of
the sample groups (Table II) (p , 0.001); patients in the VIN(1),
VSCC(1) and VSCC(2) groups were all significantly older than
those in the VIN(2) group. No other age comparisons were
significant.
Forty-one of 43 (95%) VIN(2) samples, 30 of 42 (71%)
VSCC(2) samples and 17 of 18 (94%) VSCC(1) samples were
HPV positive using consensus primers. Sequencing confirmed the
presence of HPV DNA in 73 of 74 samples. The following HPV
types were identified: 16 (92%), 33 (3%), 45 (1%), 11 (1%) and
unknown type (3%). The unknown types displayed a 85–89%
match to a known type. There was no significant difference in the
stage distribution between HPV-positive and HPV-negative
VSCC. Four of 13 HPV-negative VSCC were associated with
lichen sclerosus compared with 3 of 47 HPV-positive VSCC
(p , 0.04).
The frequency of LOH at the 6 loci studied in HPV-positive
VIN and HPV-positive and -negative VSCC are shown in Figure
3. FRL in HPV-negative VSCC compared with HPV-positive
VSCC did not differ significantly (mean FRL 0.33 vs. 0.28, p ,
0.56). LOH at 3p25 in HPV-negative VSCC occurred at a signif-
icantly higher frequency compared with HPV-positive VSCC
(58% vs. 22%, p , 0.04). The frequencies of LOH at the p53, p16
and 11p15.5 loci were higher in HPV-positive VSCC than in
HPV-positive VIN; however, these differences were not signifi-
cant.
DISCUSSION
We wanted to document and compare LOH rates in lone VIN
and VIN and VSCC occurring concurrently to assess possible
markers for progression from VIN to VSCC. Comparison of LOH
in HPV-positive and -negative VSCC might provide insight into
the pathways of vulval carcinogenesis. There have been 4 previous
reports of LOH in vulval neoplasia. The first8 studied 4 cases of
VSCC, 2 of which had adjacent VIN. This analysis was aimed at
investigating the clonal evolution of these conditions, rather than
documenting overall rates of LOH. The other studies9–11 examined
HPV status and LOH at multiple chromosomal loci in 16 cases of
TABLE II – SAMPLE TYPE AND NUMBERS, ABBREVIATIONS, MEDIAN AGE
RANGES AND AGE OF DIFFERENT SAMPLE GROUPS
Sample type (n) Abbreviation Median age(range), years
VIN III not associated with VSCC (43) VIN(2) 46 (27–83)
VSCC not associated with VIN (42) VSCC(2) 75 (21–94)
VSCC associated with VIN1 (18) VSCC(1) 63 (35–88)
VIN associated with VSCC1 (21) VIN(1) 63 (35–88)
VIN, vulval intraepithelial neoplasia; VSCC, vulval squamous cell
carcinoma.–1These samples are from the same 21 patients, but the
VSCC could not be analyzed in 3 cases in which serial sectioning had
removed the VSCC from the specimen block.
FIGURE 2 – Proportion of informative samples undergoing loss of
heterozygosity (LOH) at 6 loci in VIN(2), VIN(1) and VSCC(1).
*Significant differences between groups (p , 0.02). n, number of
informative results in each column; VIN, vulval intraepithelial neo-
plasia; VSCC, vulval squamous cell carcinoma.
FIGURE 3 – Proportion of informative samples undergoing loss of
heterozygosity (LOH) at 6 loci in HPV-positive VIN(2), HPV-posi-
tive VSCC and HPV-negative VSCC. *Significant differences be-
tween groups (p , 0.04). n, number of informative results in each
column; HPV, human papillomavirus; VIN, vulval intraepithelial neo-
plasia; VSCC, vulval squamous cell carcinoma; 1ve, positive; -ve,
negative.
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VSCC, 30 cases of VSCC (and associated VIN) and 30 cases of
VIN, respectively. We undertook a larger study, which analyzed
VIN and VSCC samples in an attempt to establish whether HPV-
positive and -negative VSCC undergo different chromosomal
losses and whether the VIN associated with invasive disease
differs from lone VIN.
The loci studied were chosen for specific reasons: 17p13 be-
cause it harbors p53, which accumulates in 53–68% of VSCC13,14
and 9p21 (p16 gene) and 3p25 because they frequently exhibit
LOH in squamous head and neck cancer.15–17 p16 is also disrupted
in VIN and VSCC.18 The other loci studied (4q21, 5p14, 11p15)
may be involved in cervical cancer.19
Clear losses were visible in VIN, suggesting that VIN is a clonal
neoplasm. LOH was frequent in both lone VIN and VSCC (53%
and 81% at 1 or more locus, respectively), suggesting that VIN,
like cervical intraepithelial neoplasia (CIN),20 frequently under-
goes LOH which may alter tumor suppressor gene function.
HPV is implicated in CIN and cervical squamous cell carcinoma
(CxSCC) as well as VIN and some VSCC.2,4,21 LOH was observed
in HPV-positive VIN and VSCC at loci frequently lost in CxSCC
(4q21, 5p14, 11p15), but at lower rates.19 Comparison with the
other studies in vulval neoplasia is difficult because most of the
microsatellite markers used differed from the present study. How-
ever, the largest of the previous studies of VSCC10 found a
significantly higher overall frequency of LOH at 7 3p loci in
HPV-negative compared with HPV-positive VSCC, although the
individual difference at 3p25 did not reach significance. Both of
the previous VSCC studies9,10 reported (nonsignificantly) higher
LOH rates at 17p in HPV-negative VSCC compared with HPV-
positive VSCC. With regards to VIN, comparison with 1 of the 2
previous studies11 is impossible, as the frequencies of LOH at
individual loci were amalgamated with results from nonneoplastic
epithelial disorders. The other study10 found a similarly low fre-
quency of LOH at the p53 locus in VIN(1); however, that study
reported 0% LOH at 3p25 in VIN(1) compared with 53% in our
study. This difference may relate to sample size, as only 7 VIN
II/III samples in the previous study were informative.
FRL in VIN(1) was significantly higher than in VIN(2), sug-
gesting that genetic instability in VIN may predispose to invasion.
In cervical neoplasia, microsatellite instability (another measure of
genetic instability) was found significantly more in intraepithelial
lesions associated with invasive disease than in lone intraepithelial
lesions.22 It could be argued that this difference in FRL in our
study resulted from the median age of patients in the VIN(1)
group being older than those in the VIN(2) group, implying that
greater LOH in VIN(1) reflects the age of the VIN and the longer
it persists, the higher the chance of developing cancer. However,
the difference in FRL remained even when we corrected for patient
age. Although this finding cannot entirely exclude the possibility
that the VIN(1) cases have existed for longer than the VIN(2)
cases, it supports the argument that the differences in FRL reflect
inherent genetic instability, rather than instability that has accu-
mulated with time.
The finding of significantly higher FRL in VIN(1) than in
VSCC(1) from the same patients is perplexing. This phenomenon
was observed in 1 of the 2 cases of concurrent VIN and VSCC in
another study8 and is exemplified in Figure 1b, in which the
VIN(1) has lost an allele at a locus not lost in the adjacent
VSCC(1). One possible explanation is that VSCC is inherently
more likely than VIN to be contaminated with nonneoplastic
stromal cells or lymphocytes, which could swamp out the neoplas-
tic DNA in the assay, thus masking LOH. We therefore scored
samples for contamination. Five of 9 VSCC(1) samples exhibiting
LOH had maximal contamination.
This finding suggested that we had successfully isolated tumor
DNA from less contaminated areas on the slides or that amplifi-
cation of tumor DNA was sufficient to swamp out any normal
DNA. Furthermore, if VSCC were more contaminated than VIN,
then VSCC would be expected to demonstrate allelic imbalance
(classified as 50–99% reduction in intensity of 1 allele), rather than
pure LOH (100% loss of 1 allele). The proportion of VSCC
samples demonstrating allelic imbalance, rather than pure LOH,
was lower than in VIN cases (38% vs. 51%, data not shown). This
finding suggests that microdissection of VSCC samples produced
cell populations at least as pure as those from VIN samples. We
therefore conclude that the finding of higher FRL in VIN(1) than
VSCC(1) is real. This finding suggests that some of the losses
observed in VIN(1) occurred after the point at which a subclone
of that VIN had acquired the malignant phenotype. We therefore
speculate that inherently unstable VIN gives rise to the invasive
phenotype, which then selects for LOH at loci different to those
which the unstable VIN continues to lose, either as a random
consequence of genetic instability, or as it evolves down a different
path from the VSCC. This theory fits the observations at the p53
locus, which, unlike the other loci studied, was lost more in
VSCC(1) than VIN(1) (Fig. 2). In a similar study of cervical
cancer22 Chu et al. observed microsatellite instability in some
cases of intraepithelial neoplasia, but not in the associated invasive
disease. This evidence supports the hypothesis of clonal evolution
in intraepithelial neoplasia and possibly the selection of a more
stable clone in invasive disease.
Disruption of p16 or RB has been found more in VSCC (72%,
n 5 32) than in VIN (60%, n 5 10).18 In our series, the p16 locus
(9p21) was lost significantly more in VIN(1) than in VIN(2) (Fig.
2). However, the lowest rate of p16 loss was observed in
VSCC(1), therefore it seems unlikely that loss of p16 is a signif-
icant event in progression. Similar nonsignificant trends were
observed with LOH at 3p25 and 11p15.5, so it also seems unlikely
that these loci are involved in progression. This conclusion is
reinforced by the relatively low frequency of LOH at these loci in
HPV-positive VSCC (Fig. 3). More probably, these losses reflect
increased genetic instability in the VIN(1) samples.
p53 may be involved in progression from VIN to VSCC as p53
product accumulated in 53% of VSCCs (n 5 66)13 and 44% (n 5
34)14 of VIN associated with VSCC, but 0% of VIN not associated
with VSCC (n 5 28).4 In our series, the p53 locus was lost more in
VSCC(1) than in VIN(1), which in turn had more loss of p53 than
VIN(2) (Fig. 2), but these differences were nonsignificant. HPV-
positive VSCC lost p53 more often than HPV-positive VIN (Fig. 3),
but the difference was not significant. Given these results and the fact
that LOH at p53 occurred in only 31% of HPV-positive VSCC, it
seems unlikely that LOH at p53 is involved in the progression of VIN
to VSCC. However, there does appear to be a possible role for LOH
at the p53 locus in HPV-negative VSCC, as 50% of informative
samples lost this locus (Fig. 3). This hypothesis concurs with another
study that found accumulation of p53 product in 53% of HPV-
negative VSCC (n 5 54).13 The observation that 58% of HPV-
negative VSCC underwent LOH at 3p25 suggests that this locus may
be the site of a tumor suppressor involved in an HPV-independent
pathway of vulval carcinogenesis. The fact that this locus was lost
significantly more in HPV-negative VSCC than in HPV-positive
VSCC (Fig. 3) supports dual etiologies in VSCC.
In conclusion, we found that genetic instability in VIN, reflected
by LOH, is associated with invasive disease. The higher rate of
LOH at 3p25 in HPV-negative compared with HPV-positive
VSCC supports the hypothesis that there are 2 different etiologies
in vulval carcinogenesis and implicates this locus as the site of a
possible tumor suppressor in an HPV-independent pathway.
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